Dual peptide blend: Ipamorelin (5mg) + Tesamorelin (5mg) — GHS-R agonist paired with GHRH analog Two distinct GH-axis receptor targets in a single co-lyophilized vial For in vitro dual-mechanism GH-axis research only
For laboratory research use only. Not for human or veterinary consumption. SKU IPTESA55.
Selective GHS-R agonist pentapeptide. CAS 170851-70-4. MW 711.85 g/mol. Characterized by Raun et al. as the first GH secretagogue with selectivity comparable to GHRH itself.
Full-length GHRH analog (all 44 amino acids) with N-terminal lipophilic stabilization. CAS 218949-48-5. MW 5135.83 g/mol. A structurally different approach to GHRH receptor agonism than the truncated, tetra-substituted CJC-1295.
GHRH receptor activation and ghrelin receptor signaling converge on pituitary somatotrophs through complementary cascades. Preclinical literature has characterized how these two inputs interact — the GHRH pathway through cAMP/PKA, the GHS-R pathway through PLC/IP3/calcium. Studying both under identical experimental conditions in a single reconstitution eliminates variability from separate preparations.
| Content | 5mg Ipamorelin + 5mg Tesamorelin per vial |
| Format | Co-lyophilized powder |
| Testing | , both components verified |
For laboratory research use only. Not for human or veterinary use.